OTCMKTS:LBTSF Almirall Earnings Date & Estimates $15.35 0.00 (0.00%) As of 10/26/2026 Almirall is estimated to report earnings on Monday, November 9, 2026. Research:ProfileForecast Upcoming Earnings Announcement Announcement DateNovember 9, 2026 Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from AlmirallAlmirall is expected to post earnings of $0.1498 per share on revenue of $354.30 million.Consensus EstimatesConsensus EPS$0.1498Expected Revenue$354.30 millionPrepare for the Earnings CallCompany Profile Almirall Earnings FAQ When does Almirall report earnings? Almirall (OTCMKTS:LBTSF) is estimated to report earnings on Monday, November 9, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What is the consensus EPS estimate for Almirall? Analysts expect Almirall to post earnings of $0.1498 per share for the quarter. How much revenue is Almirall expected to report? The consensus revenue estimate for Almirall is $354.30 million for the quarter. Almirall Earnings HeadlinesAlmirall S.A.April 20, 2026 | marketwatch.comSpain's Almirall in talks with 'dozens' of firms to license China assets, CEO saysMarch 12, 2026 | msn.comDO YOU LIVE HERE? ⬇️Data centers now number about 1,300 across the US, with another 2,500 planned. Each can draw as much power as 100,000 homes, and one Virginia homeowner saw his bill jump from $100 to $281 in a single month. Elon Musk has filed a plan with the FCC to move data centers out of cities entirely, a move backed by President Trump. One lesser-known, publicly traded company trading under $100 a share may sit at the center of that shift. | Paradigm Press (Ad)Almirall SA (LBTSF) Q4 2025 Earnings Call Highlights: Strong Sales Growth and Strategic InvestmentsFebruary 23, 2026 | uk.finance.yahoo.comAlmirall, S.A.: Almirall's 2025 ResultsFebruary 23, 2026 | finanznachrichten.deEpimAb Biotherapeutics Announces the First CTA Filing of a FIT-IG® Bispecific Antibody by its License Partner AlmirallFebruary 10, 2026 | markets.businessinsider.comSee More Almirall Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Almirall? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Almirall and other key companies, straight to your email. Email Address About AlmirallAlmirall (OTCMKTS:LBTSF) S.A. is a Barcelona-based pharmaceutical company focused on medical dermatology. The company develops, manufactures and commercializes prescription medicines for conditions including psoriasis, acne, atopic dermatitis, actinic keratosis and other skin diseases. Its portfolio includes treatments such as Ilumetri (tildrakizumab) for plaque psoriasis, Klisyri (tirbanibulin) for actinic keratosis, Wynzora for plaque psoriasis, and other therapies marketed under brands including Aklief, Seysara and Skilarence. Almirall also conducts research and development in areas such as inflammatory and immunological skin disorders. Founded in 1943 by the Gallardo family, Almirall serves healthcare professionals and patients across Europe and in other international markets, including the United States through commercial operations and partnerships. The company is headquartered in Spain and maintains research, manufacturing and commercial activities in several countries.View Almirall ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple's Foldable iPhone Sold Out in Minutes, But Wall Street Has QuestionsCoca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest StrengthWhirlpool's Stock Collapse Raises a Bigger Question About Its Recovery PotentialAnalysts Turn Bullish on Meta Platforms Despite Post-Earnings FallLockheed Martin's F-35 Deal Could Change How Wall Street Values the StockIntel's $155 Price Target Raises a Bigger Question About Its Turnaround PotentialMerck and Moderna's Cancer Vaccine Worked—Who Gets Paid? Upcoming Earnings Starbucks (10/29/2026)Amazon.com (10/29/2026)Anheuser-Busch InBev SA/NV (10/29/2026)Mondelez International (10/29/2026)Altria Group (10/29/2026)Cheniere Energy (10/29/2026)TotalEnergies (10/29/2026)Republic Services (10/29/2026)CRH (10/29/2026)BP (10/30/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
